Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HIV multiantigen vaccine - Bavarian Nordic

Drug Profile

HIV multiantigen vaccine - Bavarian Nordic

Alternative Names: 2E8 TCID50 MVA-mBN120B - Bavarian Nordic; MVA-BN HIV multiantigen; MVA-HIV multiantigen vaccine MVA-mBN120B - Bavarian Nordic; MVA-mBN120B

Latest Information Update: 29 Sep 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bavarian Nordic
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - HIV-1 infections

Highest Development Phases

  • Discontinued HIV-1 infections

Most Recent Events

  • 29 May 2008 Phase-I/II clinical trials in HIV-1 infections in USA (SC)
  • 29 Apr 2008 Preclinical trials in HIV-1 infections in USA (Parenteral)
  • 29 Apr 2008 Bavarian Nordic files an IND application with the USA FDA to begin a phase I/II trial for treatment of HIV-1 infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top